Iqvia (IQV) Q3 2026 earnings review
Iqvia wins more trial orders, but acquisitions carry its outlook
Iqvia, which runs clinical trials and sells drug-launch data to pharmaceutical companies, won new trial contracts faster while cleaning out old ones. Revenue rose 8% and profit per share excluding one-offs climbed 11%, both beating the top of the company's plan. Chairman and chief executive Ari Bousbib reported the strongest quarterly clinical trial orders since 2022 and raised the full-year outlook, though by our math the plan points to revenue growth slowing to 3% in the fourth quarter.
| Revenue | $4,428M +8.0% from a year ago (+8.6% at constant currency) |
|---|---|
| R&DS net new bookings | $3.2B +15% from a year ago (1.2x book-to-bill) |
| Profit per share, excluding one-offs | $3.34 +11.3% from a year ago |
| Full-year revenue outlook | Raised $50M middle of the range: 6.8% growth |
⚖️ Verdict: 🟢 Bullish
The story got better because clinical trial orders are now turning into near-term revenue, with backlog scheduled to convert over the next twelve months growing 10% versus 8% last quarter. Pausing share buybacks also brought debt leverage down for the first time this year. The bad news: Iqvia wrote off $2.1 billion of inactive trials from its backlog, and extra acquisitions accounted for more than all of the full-year revenue outlook raise by our math.
The question now is whether the fourth-quarter slowdown implied by the full-year plan is just management's usual caution against a tough year-ago comparison or a sign that underlying growth is cooling. Optimists point to rising trial orders and biotechnology funding, while skeptics point to the backlog write-down and reliance on unclosed acquisitions. Management's multi-year targets at the December 1 Investor Day and fourth-quarter results will settle it.
🐂 Bull Case
Clinical Trial Bookings and Next-Year Conversion Accelerate
"Multiple demand indicators continue to validate the strengthening market environment," chief executive Ari Bousbib said. In Research & Development Solutions (R&DS), the unit that runs clinical trials for drugmakers, Bousbib pointed to favorable funding for emerging biopharma (EBP) — smaller biotech firms — alongside rising requests for proposals and US drug approvals. Those industry tailwinds helped Iqvia win $3.2 billion of net new trial contracts, up 15% from a year ago for "our strongest clinical quarterly bookings since 2022".
The book-to-bill ratio — new orders divided by revenue — reached 1.2x in the quarter, lifting orders over the last twelve months by 14% to $11.7 billion. More importantly, the portion of trial backlog that the company expects to turn into revenue over the next twelve months rose 10% from a year ago to $9.4 billion, accelerating from 7.5% growth in the second quarter because recent contract wins are moving into active trial phases.
What to watch: next-twelve-month revenue from backlog in the fourth quarter. Another reading at or above 10% growth would confirm that strong trial orders are turning into 2027 revenue on schedule.
Commercial Solutions and Underlying Clinical Growth Step Up
Iqvia sells drug-launch data, software, and consulting through its Commercial Solutions division alongside its clinical trial business. Bousbib said faster client spending across both units drove "organic growth acceleration year-over-year to double the rate for commercial and nearly triple the rate for clinical". Commercial Solutions revenue rose 6.9% to $1,789 million, or 7.9% at constant currency, as pharmaceutical clients spent more on launching new medicines.
R&DS revenue increased 8.7% to $2,639 million, or 9.1% at constant currency, beating the pace of the first half. Because both divisions accelerated on an underlying basis against a softer year-ago comparison, the healthcare data group topped its third-quarter revenue target by $75.5 million at the middle of the range.
What to watch: exact underlying sales growth rates for both segments in the quarterly filing or call transcript. Those figures will show how much of the third-quarter acceleration came from existing operations rather than recent acquisitions.
Net Leverage Drops as Buybacks Pause
Rising debt and interest costs have been a persistent concern after Iqvia borrowed money over the past two years to fund acquisitions and share buybacks. In the third quarter, the clinical research provider paused share repurchases entirely, keeping nine-month buybacks at $950 million, unchanged from the first half by our math. Instead, it directed cash flow toward paying down its revolving credit line.
That shift reduced net debt — total debt minus cash — by $272 million from last quarter to $13,818 million. Net debt fell to 3.45x trailing twelve-month profit before interest, taxes, depreciation, and amortization, excluding one-offs, down from 3.59x in June and 3.63x at the end of 2025. One quarter of debt paydown eases the balance-sheet concern without yet resolving it, because net interest expense still rose 8.5% from a year ago to $191 million.
What to watch: fourth-quarter share repurchases and acquisition spending. The full-year outlook includes unclosed deals, which could push leverage back up before year-end.
🐻 Bear Case
Backlog Review Cuts $2.1 Billion of Inactive Trials
Last quarter, management told investors it was reviewing stalled clinical trials in its order book and estimated a potential reduction of roughly 5%. This quarter, Iqvia completed "a detailed review of inactive trials in our backlog estimates" and removed $2.1 billion, or 6.1% of the second quarter's $34.2 billion contracted backlog by our math. Because of that write-down, total contracted backlog fell by $1.6 billion from June to $32.6 billion.
- Reported R&DS contracted backlog: $32.6 billion, down $1.6 billion from last quarter
- Inactive trial removal: $2.1 billion, or 6.1% of prior backlog by our math
- Clean backlog change before the write-down: up $0.5 billion from last quarter by our math
- Net new bookings excess over R&DS revenue: roughly $0.56 billion ($3.2 billion orders vs $2.64 billion sales)
The company stated the removal has "no impact on historical financial results, 2026 guidance, book-to-bill, or next-twelve-month revenue from backlog estimates". Even so, cutting more than $2 billion of previously reported orders shows that past bookings included trials that never ran, and it leaves the total order book barely higher than the $32.4 billion reported a year ago.
What to watch: the complete backlog roll-forward on the conference call or at the December 1 Investor Day. Investors need to see whether normal quarterly cancellations also rose alongside this one-time cleanup.
Acquisitions Carry the Outlook Raise as Q4 Slows
Bousbib highlighted accelerating underlying sales growth in the third quarter and raised the full-year revenue outlook by $50 million at the middle of the range, to $17,350–17,500 million. However, the release notes that the new plan includes 2.5 percentage points of growth from acquisitions — up from 2.0 percentage points in July — "including acquisitions the company expects to complete by the end of the year".
That extra 0.5 percentage points of acquisition contribution equals roughly $80 million of revenue by our math, which is more than the entire $50 million increase to the full-year midpoint. Furthermore, after subtracting nine-month revenue of $12,947 million, the full-year plan leaves $4,403–4,553 million for the fourth quarter by our math. That points to just 2.6% growth at the middle of the range, down from 8.0% in the third quarter, even after accounting for a tougher comparison against last year's 10.3% fourth-quarter growth.
What to watch: fourth-quarter revenue against the $4,478 million implied midpoint. A result near that mark would mean underlying growth slowed sharply at year-end despite upbeat order commentary.
Pass-Through Costs and Overhead Weigh on Operating Margins
While Bousbib noted that execution delivered margin expansion — with profit before interest, taxes, depreciation, and amortization, excluding one-offs, up 0.2 percentage points to 23.3% of revenue — statutory operating margin fell 0.6 percentage points from a year ago to 12.9%. In R&DS, total revenue grew 8.7%, but revenue excluding reimbursed pass-through expenses grew 6.8%, meaning zero-margin pass-through costs grew much faster than service fees.
- Cost of revenues (cost of delivering services, excluding depreciation): 66.2% of sales, down 0.3 percentage points from a year ago by our math
- Selling, general and administrative (overhead and sales): 12.8% of sales, up 0.3 percentage points by our math
- Depreciation and amortization: 7.2% of sales, up 0.3 percentage points by our math
- Restructuring charges: $36 million, or 0.8% of sales, up 0.3 percentage points by our math
Higher overhead, acquisition amortization, and ongoing restructuring absorbed the gross margin gain, causing pre-tax profit to fall 5.4% to $386 million by our math. Statutory net income only rose 5.7% to $350 million because Iqvia recorded a $42 million gain from unconsolidated affiliates, compared with nothing a year ago.
What to watch: restructuring charges and pass-through revenue mix in the fourth quarter. Continued quarterly restructuring above $30 million would keep statutory earnings lagging behind the company's headline profit measures.
AI Agent Rollout Crosses 400 Without Revenue Disclosure
Iqvia views artificial intelligence as a growth driver that speeds up clinical trials and analytics, while critics worry that general-purpose AI tools will let drugmakers do data work in-house and demand lower prices. This quarter, Bousbib pointed to "over 400 AI agents deployed to date", up from 294 software agents at the end of June.
Despite rapid deployment across client workflows, the earnings release gives no dollar figure for revenue earned from AI products and does not say whether these tools raise contract prices or merely replace existing consulting work. Until management separates AI sales from standard contract renewals, rapid agent counts alone do not settle the debate over whether automation expands or shrinks the company's billing base.
What to watch: AI revenue and pricing disclosures at the December 1 Investor Day. A concrete dollar figure for incremental AI contracts would test whether these 400 software agents bring in new spending.
💲 Other KPIs
Free cash flow fell 13.6% from a year ago by our math, as operating cash flow dropped to $825 million from $908 million and capital spending rose to $158 million. Even so, cash generation rebounded from $360 million in the second quarter and equaled 120% of profit excluding one-offs, lifting nine-month free cash flow 1.9% to $1,518 million.
Unearned income — cash customers have paid upfront for clinical and commercial work not yet performed — rose 9.2% from the end of 2025 by our math, outpacing nine-month revenue growth of 8.4%. Over the same nine months, trade accounts receivable and unbilled services fell 3.1% to $3,293 million, showing faster customer billings and collections.
Weighted average diluted shares declined 2.7% from 171.7 million a year ago by our math, adding roughly 2.6 percentage points to per-share profit growth. Compared with the second quarter's 167.3 million shares, the count barely moved because the healthcare services group bought back no stock during the third quarter.
🔮 Guidance
Raised. The middle of the full-year range moved up $50 million to $17,425 million, or 6.8% growth by our math (4.1% excluding acquisitions and currency). That follows moves of $0, +$125 million, and +$50 million across the year. By our math, the plan leaves 2.6% growth for Q4 against a 10.3% year-ago base, or 4.4% if the 1.7% quarterly beat pattern holds.
Raised. Management lifted the middle of the range by $15 million to $4,040 million, or 6.7% growth for the year by our math, after raising it $25 million in July. By our math, that leaves $1,082 million for the fourth quarter, up 3.4% from a year ago compared with 8.7% growth in the third quarter.
Raised. Iqvia brought up the bottom of the range by $0.10, lifting the middle by $0.05 to $12.95, or 8.6% full-year growth by our math. It is the third raise this year, and each is smaller or equal: +$0.10, +$0.10, +$0.05. By our math, the outlook leaves $3.57 for the fourth quarter, up 4.4% from a year ago.
❓ Key Questions
Why did Iqvia omit an explicit fourth-quarter outlook?
In prior quarters, the release or call notes provided explicit next-quarter ranges alongside the full-year plan. With only full-year numbers in the release, investors must infer a sharp fourth-quarter slowdown to 2.6% revenue growth by our math.
Which unclosed acquisitions are inside the 2026 revenue plan?
The raised revenue outlook assumes 2.5 percentage points of acquisition growth, including deals not yet closed. Management has not named these targets, their purchase price, or how much fourth-quarter revenue depends on closing them on time.
What is the complete roll-forward for the $32.6B backlog?
Removing $2.1 billion of inactive trials leaves a $0.5 billion clean backlog increase from last quarter by our math, roughly matching the $0.56 billion excess of orders over sales. A full bridge would show whether currency or normal cancellations also moved the total.
How much new revenue do the 400 AI agents generate?
Deployed AI agents jumped from 294 in June to over 400 in September. Without figures on AI contract pricing or incremental sales, it is impossible to tell whether these tools bring in new budgets or just defend existing accounts.